Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLS2 | Q9UI32 | 3/20 | 0.39 |
| ▸ | PRKCA | P17252 | 2/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | PDCD4 | Q53EL6 | 2/20 | 0.33 |
| ▸ | FAAH | O00519 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TLR2 | O60603 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19681577 | 0.95 | GLS2 (0.38) | GLS2PRKCALTA4HEPHX2PDCD4 | |
| SCHEMBL19681590 | 0.94 | GLS2 (0.37) | GLS2PRKCALTA4HEPHX2PDCD4 | |
| SCHEMBL25681486 | 0.86 | GLS2 (0.35) | GLS2PRKCALTA4HEPHX2PDCD4 | |
| SCHEMBL19681510 | 0.82 | TLR2 (0.31) | EPHX2TLR2 | |
| SCHEMBL19681580 | 0.79 | GPR84 (0.39) | EPHX2TP53 | |
| SCHEMBL24787485 | 0.78 | DNM1 (0.33) | GLS2EPHX2FAAHTLR2 | |
| SCHEMBL19681591 | 0.77 | BBOX1 (0.39) | GLS2PRKCA | |
| SCHEMBL19681581 | 0.77 | ADRA1D (0.37) | GLS2PRKCAEPHX2 | |
| SCHEMBL25681562 | 0.76 | GLS2 (0.35) | GLS2PRKCALTA4HEPHX2 | |
| SCHEMBL23124033 | 0.76 | MAPK1 (0.46) | PRKCAEPHX2TP53TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170349543-A1 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170349543-A1 | CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS | ABHD16A, AARS1, CFTR | GLS2 74/4885PRKCA 2583/4885LTA4H 832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.